Masimo Reports Strong Preliminary 2025 Results, Outlines Ambitious Long-Range Plan
Summary
Masimo reported preliminary Q4 and full-year 2025 results exceeding guidance and unveiled a positive long-range plan, signaling strong operational performance and future growth.
Key Events
-
Preliminary 2025 Financial Results
Masimo reported preliminary Q4 2025 revenue of approximately $411 million (12% growth) and full-year 2025 revenue of approximately $1,523 million (9% growth).
-
Exceeds EPS Guidance
Non-GAAP earnings per diluted share for full-year 2025 are expected to be more than $5.55, reaching the high end of the company's guidance range.
-
Long-Range Strategic Plan
The company presented a long-range plan through 2028, targeting 7%-10% revenue CAGR, $8.00 adjusted EPS, and approximately $1 billion in cumulative operating cash flow.
-
J.P. Morgan Healthcare Conference
These preliminary results and the strategic plan were disclosed in conjunction with the company's participation at the 44th Annual J.P. Morgan Healthcare Conference.
Analysis
Masimo Corporation announced preliminary financial results for Q4 and full-year 2025, with revenue growth and non-GAAP EPS exceeding the high end of its guidance range. This strong performance, coupled with an ambitious long-range plan presented at the J.P. Morgan Healthcare Conference, suggests positive momentum and strategic clarity for investors. The company's focus on core medical technology, market share expansion, and new product launches underpins its targets for significant revenue growth, margin expansion, and cash generation through 2028.
At the time of this filing, MASI was trading at $140.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $125.94 to $194.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.